
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MRNA | NASDAQ | USD | Real-time | |
MRNA | Mexico | MXN | Delayed | |
MRNA | Milan | EUR | Real-time | |
0QF | TradeGate | EUR | Delayed | |
0QF | Frankfurt | EUR | Delayed | |
MRNA_KZ | KASE | USD | Delayed | |
MRNA | Lima | USD | Delayed |
Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.
Name | Age | Since | Title |
---|---|---|---|
Robert S. Langer | 73 | 2010 | Independent Non Executive Director & Member of Scientific Advisory Board |
Jack W. Szostak | - | 2014 | Chairman of Scientific Advisory Board |
Elizabeth Edith Tallett | 72 | 2020 | Independent Director |
Scott A. Canute | 61 | 2014 | Member of Technology Advisory Board |
Ulrich H. von Andrian-Werburg | - | - | Member of Scientific Advisory Board |
Fred E. Regnier | - | 2014 | Member of Technology Advisory Board |
Richard C. Willson | - | 2014 | Member of Technology Advisory Board |
John G. Aunins | 61 | 2014 | Member of Technology Advisory Board |
James R. Swartz | - | 2014 | Member of Technology Advisory Board |
Sandra J. Horning | 73 | 2020 | Independent Director |
Elizabeth G. Nabel | 70 | 2021 | Independent Director |
Noubar B. Afeyan | 60 | 2010 | Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board |
Stephane Bancel | 50 | 2011 | CEO & Director |
Melissa J. Moore | - | 2016 | Chief Scientific Officer & Member of Scientific Advisory Board |
Ron Eydelloth | - | - | Member of Scientific Advisory Board |
Rachel Green | - | - | Member of Scientific Advisory Board |
Paul L. Sagan | 64 | 2018 | Independent Non Executive Director |
Ralph Weissleder | - | - | Member of Scientific Advisory Board |
Paula T. Hammond | 59 | - | Member of Scientific Advisory Board |
Michael Diamond | - | - | Member of Scientific Advisory Board |
Stephen A. Berenson | 62 | 2017 | Independent Non Executive Director |
Francois Nader | 66 | 2019 | Independent Non Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review